Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Goergen

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Vaccine|January 19, 2021
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)Jennifer A Whitaker, Sameer A Parikh, Tait D Shanafelt, et al.
Gynecologic Oncology|December 21, 2020
Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancerAllyson C Banville, Maartje C A Wouters, Ann L Oberg, et al.
Gynecologic Oncology|January 27, 2015
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicAndrea E Wahner Hendrickson, Kieran M Hawthorne, Ellen L Goode, et al.
Scientific Reports|April 14, 2021
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) settingAnn L Oberg, Ethan P Heinzen, Xiaonan Hou, et al.
Oncotarget|October 6, 2015
Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersChristine Mehner, Ann L Oberg, Kimberly R Kalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian CancerArtur A Serebrenik, Prokopios P Argyris, Matthew C Jarvis, et al.
Cancers|December 10, 2021
CHFR and Paclitaxel Sensitivity of Ovarian CancerAndrea E Wahner Hendrickson, Daniel W Visscher, Xiaonan Hou, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Surgical Endoscopy|October 5, 2002
Laparoscopic liver resection of benign liver tumorsB Descottes, D Glineur, F Lachachi, et al.
JCO Oncology Advances|April 1, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark AnalysisLuigi A De Vitis, Melissa C Larson, Hunter J Atkinson, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Vaccine|January 19, 2021
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)Jennifer A Whitaker, Sameer A Parikh, Tait D Shanafelt, et al.
Gynecologic Oncology|December 21, 2020
Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancerAllyson C Banville, Maartje C A Wouters, Ann L Oberg, et al.
Gynecologic Oncology|January 27, 2015
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicAndrea E Wahner Hendrickson, Kieran M Hawthorne, Ellen L Goode, et al.
Scientific Reports|April 14, 2021
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) settingAnn L Oberg, Ethan P Heinzen, Xiaonan Hou, et al.
Oncotarget|October 6, 2015
Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancersChristine Mehner, Ann L Oberg, Kimberly R Kalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian CancerArtur A Serebrenik, Prokopios P Argyris, Matthew C Jarvis, et al.
Cancers|December 10, 2021
CHFR and Paclitaxel Sensitivity of Ovarian CancerAndrea E Wahner Hendrickson, Daniel W Visscher, Xiaonan Hou, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Surgical Endoscopy|October 5, 2002
Laparoscopic liver resection of benign liver tumorsB Descottes, D Glineur, F Lachachi, et al.
JCO Oncology Advances|April 1, 2026
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark AnalysisLuigi A De Vitis, Melissa C Larson, Hunter J Atkinson, et al.
Pageof 7